Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -124.97% is 102% below its 5-year average of -61.73%, near the high end of its 5-year range (-692.77%–-35.67%).
As of the fiscal period ended Tuesday, June 30, 2026. 59.90% below its 12-month average of -78.16%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -124.97%.
RETURN ON EQUITY (ROE)
-124.97%
RETURN ON EQUITY (ROE) AVG TTM
-78.16%
RETURN ON EQUITY (ROE) AVG 3Y
-64.66%
RETURN ON EQUITY (ROE) AVG 5Y
-61.73%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-59.90%
CURRENT VS 3Y AVG
-93.29%
CURRENT VS 5Y AVG
-102.45%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-197.49%
vs the sector median at left
NEXGEL, Inc.
Market Cap
$1.45M
Return on Equity (ROE)
-124.97%
TTM Avg
-78.16%
3Y Avg
-64.66%
5Y Avg
-61.73%
Market Cap
$1.44M
Return on Equity (ROE)
-450.54%
TTM Avg
292.29%
3Y Avg
55.45%
5Y Avg
24.80%
Market Cap
$1.42M
Return on Equity (ROE)
-32.05%
TTM Avg
-197.10%
3Y Avg
-44.98%
5Y Avg
-69.38%
Market Cap
$1.49M
Return on Equity (ROE)
-80.57%
TTM Avg
-96.07%
3Y Avg
-115.92%
5Y Avg
51.19%
Market Cap
$1.51M
Return on Equity (ROE)
-169.64%
TTM Avg
97.92%
3Y Avg
65.28%
5Y Avg
65.28%
Market Cap
$1.37M
Return on Equity (ROE)
-253.57%
TTM Avg
334.28%
3Y Avg
134.39%
5Y Avg
95.16%
Market Cap
$1.35M
Return on Equity (ROE)
N/A
TTM Avg
206.72%
3Y Avg
141.32%
5Y Avg
115.74%
Market Cap
$1.33M
Return on Equity (ROE)
-114.48%
TTM Avg
-127.66%
3Y Avg
-155.08%
5Y Avg
-465.16%
Market Cap
$1.32M
Return on Equity (ROE)
-111.51%
TTM Avg
-753.43%
3Y Avg
-507.39%
5Y Avg
-356.28%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NEXGEL, Inc. (NXGL) | $1.45M | -124.97% | -78.16% | -64.66% | -61.73% |
| Curis, Inc. (CRIS)vs › | $1.44M | -450.54% | 292.29% | 55.45% | 24.80% |
| INVO Fertility, Inc. (IVF)vs › | $1.42M | -32.05% | -197.10% | -44.98% | -69.38% |
| PMGC Holdings Inc. (ELAB)vs › | $1.49M | -80.57% | -96.07% | -115.92% | 51.19% |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.51M | -169.64% | 97.92% | 65.28% | 65.28% |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.37M | -253.57% | 334.28% | 134.39% | 95.16% |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.35M | N/A | 206.72% | 141.32% | 115.74% |
| NewcelX Ltd. (NCEL)vs › | $1.33M | -114.48% | -127.66% | -155.08% | -465.16% |
| Genprex, Inc. (GNPX)vs › | $1.32M | -111.51% | -753.43% | -507.39% | -356.28% |
| Silo Pharma, Inc. (SILO)vs › | $1.65M | -91.52% | -77.16% | -63.00% | -74.35% |
ROE
-125.0%
ROA
-23.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -124.97% |
| 2026-03-31 | -80.50% |
| 2025-12-31 | -67.28% |
| 2025-09-30 | -55.53% |
| 2025-06-30 | -62.51% |
| 2025-03-31 | -60.28% |
| 2024-12-31 | -57.01% |
| 2024-09-30 | -75.29% |
| 2024-06-30 | -81.26% |
| 2024-03-31 | -66.75% |
| 2023-12-31 | -67.21% |
| 2023-09-30 | -47.51% |
| 2023-06-30 | -54.75% |
| 2023-03-31 | -54.39% |
| 2022-12-31 | -62.14% |
| 2022-09-30 | -69.81% |
| 2022-06-30 | -60.46% |
| 2022-03-31 | -52.82% |
| 2021-12-31 | -35.67% |
| 2021-09-30 | -692.77% |
| 2021-03-31 | -246.00% |
| 2020-09-30 | -506.68% |
| 2020-06-30 | -289.34% |
| 2020-03-31 | -327.16% |
| 2019-12-31 | -506.05% |
| 2019-03-31 | -985.78% |
| 2018-12-31 | -702.85% |
| 2018-09-30 | -297.59% |
